MAIA Biotechnology Accelerates NSCLC Trial Enrollment, Eyes 2027 Interim Data — MAIA Biotechnology, Inc.

Event summary

MAIA Biotechnology has dosed 29 patients in its Phase 3 THIO-104 trial for third-line NSCLC, with 34 active sites across 6 countries.
The company targets 100 patients enrolled by year-end 2026, with interim survival data expected in 2027.
Ateganosine, the lead therapy, showed median overall survival of 17.8 months in Phase 2 vs. 5.8 months with standard chemotherapy.
The $70 billion global NSCLC treatment market by 2030 presents substantial commercial opportunity.

The big picture

MAIA's progress in its Phase 3 trial represents a critical inflection point for ateganosine, a first-in-class telomere-targeting therapy. The strong enrollment and dosing momentum come as the NSCLC treatment market continues to evolve, with increasing focus on targeted immunotherapies for late-line patients. The company's ability to deliver positive interim data in 2027 could significantly alter the competitive dynamics in this high-value indication.

What we're watching

Trial Execution: Whether MAIA can sustain current enrollment momentum to meet its year-end target.
Regulatory Pathway: The impact of FDA Fast Track designation on potential accelerated approval timelines.
Commercial Potential: How Phase 3 data may position ateganosine in the competitive NSCLC treatment landscape.